

Mathieu F Chevalier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5077229/publications.pdf>

Version: 2024-02-01

32
papers

1,428
citations

471509

17
h-index

477307

29
g-index

32
all docs

32
docs citations

32
times ranked

2624
citing authors

#	ARTICLE	IF	CITATIONS
1	Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients. <i>European Urology Focus</i> , 2022, 8, 748-751.	3.1	6
2	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. <i>Cancer Discovery</i> , 2022, 12, 958-983.	9.4	10
3	Real-world characteristics of T-cell apheresis and clinical response to Atisagenlecleucel in B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 4657-4660.	5.2	11
4	Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. <i>Blood</i> , 2022, 140, 1305-1321.	1.4	23
5	Association of Plasma Soluble Vascular Cell Adhesion Molecule-1 and sCD14 With Mortality in HIV-1-Infected West African Adults With High CD4 Counts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 138-145.	2.1	6
6	Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. , 2021, 9, .		2
7	Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients. <i>European Urology Open Science</i> , 2021, 34, 79-82.	0.4	5
8	Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. , 2021, 9, e003123.		11
9	The multifaceted immune regulation of bladder cancer. <i>Nature Reviews Urology</i> , 2019, 16, 613-630.	3.8	123
10	Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-mediated Tumor Regression in the MB49 Bladder Cancer Model. <i>Cancer Immunology Research</i> , 2019, 7, 621-629.	3.4	26
11	The pro- and anti-tumor role of ILC2s. <i>Seminars in Immunology</i> , 2019, 41, 101276.	5.6	19
12	Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization. <i>Frontiers in Immunology</i> , 2019, 10, 622.	4.8	55
13	β T-cell subsets in HIV controllers. <i>Aids</i> , 2019, 33, 1283-1292.	2.2	22
14	Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. <i>European Urology</i> , 2018, 74, 540-544.	1.9	53
15	Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. <i>Oncolimmunology</i> , 2017, 6, e1265720.	4.6	19
16	Interleukin-1 receptor antagonist, a biomarker of response to anti-TB treatment in HIV/TB co-infected patients. <i>Journal of Infection</i> , 2017, 74, 456-465.	3.3	9
17	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. <i>Nature Communications</i> , 2017, 8, 593.	12.8	175
18	Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. <i>European Urology</i> , 2017, 71, 854-857.	1.9	22

#	ARTICLE	IF	CITATIONS
19	ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. <i>Journal of Clinical Investigation</i> , 2017, 127, 2916-2929.	8.2	176
20	CD4 T-Cell Responses in Primary HIV Infection: Interrelationship with Immune Activation and Virus Burden. <i>Frontiers in Immunology</i> , 2016, 7, 395.	4.8	17
21	Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 390-398.	2.1	10
22	Phenotype Alterations in Regulatory T-Cell Subsets in Primary HIV Infection and Identification of Tr1-like Cells as the Main Interleukin 10-Producing CD4+ T Cells. <i>Journal of Infectious Diseases</i> , 2015, 211, 769-779.	4.0	37
23	Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. <i>Oncolmmunology</i> , 2015, 4, e1016697.	4.6	11
24	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. <i>Oncolmmunology</i> , 2015, 4, e1029702.	4.6	17
25	Immunotherapeutic strategies for bladder cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 977-981.	3.3	6
26	T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection. <i>Aids</i> , 2014, 28, 1683-1687.	2.2	18
27	The split personality of regulatory T cells in HIV infection. <i>Blood</i> , 2013, 121, 29-37.	1.4	192
28	The Th17/Treg Ratio, IL-1RA and sCD14 Levels in Primary HIV Infection Predict the T-cell Activation Set Point in the Absence of Systemic Microbial Translocation. <i>PLoS Pathogens</i> , 2013, 9, e1003453.	4.7	91
29	Level of double negative T cells, which produce TGF- β^2 and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection. <i>Aids</i> , 2012, 26, 139-148.	2.2	52
30	The early Th17/Treg ratio predicts the immune activation set point in patients with primary HIV infection. <i>Retrovirology</i> , 2012, 9, .	2.0	0
31	HIV-1-Specific Interleukin-21 ⁺ CD4 ⁺ T Cell Responses Contribute to Durable Viral Control through the Modulation of HIV-Specific CD8 ⁺ T Cell Function. <i>Journal of Virology</i> , 2011, 85, 733-741.	3.4	173
32	Epithelial adhesion molecules can inhibit HIV-1-specific CD8+ T-cell functions. <i>Blood</i> , 2011, 117, 5112-5122.	1.4	31